503610-43-3
503610-43-3
Chemical Structure
Rosuvastatin lactone
- CAS No.: 503610-43-3
- Formula:C22H26FN3O5S
- Molecular Weight:463.52
IUPAC Name: N-(4-(4-fluorophenyl)-5-((E)-2-((2S,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl)vinyl)-6-isopropylpyrimidin-2-yl)-N-methylmethanesulfonamide
InChIKey: SOEGVMSNJOCVHT-VEUZHWNKSA-N
SMILES: CC(C1=C(C(C(C=C2)=CC=C2F)=NC(N(C)[S](C)(=O)=O)=N1)/C=C/[C@@H](OC3=O)C[C@H](C3)O)C
Biological Activity: Rosuvastatin lactone is a metabolite of Rosuvastatin (HY-17504A) (HMG-CoA inhibitor)[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Rosuvastatin lactone | 98.88% | Rosuvastatin lactone is a metabolite of Rosuvastatin (HY-17504A) (HMG-CoA inhibitor). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Rosuvastatin lactone (Standard) | ≥98% | Rosuvastatin lactone (Standard) is the analytical standard of Rosuvastatin lactone. This product is intended for research and analytical applications. Rosuvastatin lactone is a metabolite of Rosuvastatin (HY-17504A), a statin lipid-lowering agent and HMG-CoA inhibitor. Rosuvastatin lactone exhibits endothelium-independent and HMG-CoA reductase-independent vasorelaxant activity in rat aortic rings, and its vasorelaxant effect is jointly mediated by NO produced by inducible nitric oxide synthase (iNOS) located in vascular smooth muscle and activation of potassium channels. Rosuvastatin lactone itself has no lipid-lowering effect. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Rosuvastatin lactone-d6 | Rosuvastatin lactone-d6 is the deuterium labeled Rosuvastatin lactone. Rosuvastatin lactone is a metabolite of Rosuvastatin (HY-17504A), a statin lipid-lowering agent and HMG-CoA inhibitor. Rosuvastatin lactone exhibits endothelium-independent and HMG-CoA reductase-independent vasorelaxant activity in rat aortic rings, and its vasorelaxant effect is jointly mediated by NO produced by inducible nitric oxide synthase (iNOS) located in vascular smooth muscle and activation of potassium channels. Rosuvastatin lactone itself has no lipid-lowering effect. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
